Upon ligand-receptor binding, tumor-derived IL-6 plays a crucial role in promoting MDSC chemotaxis within the TIME by activating the JAK/STAT3 and NF-κB signaling pathways [43, 44]. Here, IL6 is linked to neoplasm.